| 2011- | SK, | Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling |
| - | in-vitro, | Nor, | HL7702 | - | in-vivo, | Nor, | NA |
| 1280- | SK, | Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells |
| - | in-vitro, | GC, | AGS |
| 1281- | SK, | Enhancement of NK cells proliferation and function by Shikonin |
| - | in-vivo, | Colon, | Caco-2 |
| 1284- | SK, | Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy |
| - | in-vitro, | Melanoma, | RPMI-8226 | - | in-vitro, | Melanoma, | U266 |
| 977- | SK, | A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
| 965- | SK, | Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 |
| 1050- | SK, | Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation |
| - | in-vitro, | Colon, | CT26 |
| 1073- | SK, | Chemo, | Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 1049- | SK, | Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2 |
| - | in-vivo, | NA, | NA |
| 5102- | SK, | GEM, | Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway |
| 5103- | SK, | Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor |
| - | in-vitro, | NSCLC, | A549 |
| 5101- | SK, | Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis |
| - | vitro+vivo, | CRC, | SW-620 | - | vitro+vivo, | CRC, | HCT116 |
| 5100- | SK, | Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression |
| - | vitro+vivo, | NPC, | NA |
| 5104- | SK, | Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression. |
| - | in-vitro, | GC, | AGS |
| 1133- | SM, | Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia |
| - | in-vitro, | Nor, | HPAECs |
| 1068- | SM, | Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA | - | Human, | BC, | NA |
| 1193- | SM, | Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways |
| - | in-vivo, | Alcohol, | NA | - | in-vitro, | Liver, | HepG2 |
| 1192- | SM, | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1 |
| - | in-vitro, | GC, | AGS | - | in-vitro, | Liver, | HepG3 |
| 1191- | SM, | Salvia miltiorrhiza extract inhibits TPA‑induced MMP‑9 expression and invasion through the MAPK/AP‑1 signaling pathw |
| - | in-vitro, | BC, | MCF-7 |
| 1194- | SM, | Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/β-catenin and TGF-β signaling inhibition |
| - | in-vivo, | Diabetic, | NA |
| 1195- | SM, | Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 1291- | SM, | Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios |
| - | in-vitro, | BC, | MDA-MB-231 |
| 5790- | Sper, | The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial |
| - | Trial, | Nor, | NA |
| 5789- | Sper, | Long-term oral polyamine intake increases blood polyamine concentrations |
| - | Human, | Nor, | NA |
| 5794- | Sper, | Spermidine induces autophagy by inhibiting the acetyltransferase EP300 |
| - | in-vitro, | Nor, | U2OS |
| 5806- | Sper, | Spermidine – an old molecule with a new age-defying immune function |
| 5805- | Sper, | The Effect of Spermidine Supplementation on Cognitive Function in Adults: A Mini-Review |
| - | Review, | AD, | NA |
| 5802- | Sper, | Spermidine reduces cancer-related mortality in humans |
| - | Review, | Var, | NA |
| 5782- | Sper, | Cardioprotection and lifespan extension by the natural polyamine spermidine |
| - | in-vivo, | Nor, | NA |
| 5799- | Sper, | The positive effect of spermidine in older adults suffering from dementia : First results of a 3-month trial |
| - | Trial, | AD, | NA |
| 4891- | Sper, | Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4892- | Sper, | erastin, | Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | Pca, | NA |
| 4893- | Sper, | immuno, | Chemoproteomic Identification of Spermidine-Binding Proteins and Antitumor-Immunity Activators |
| - | in-vitro, | Var, | NA |
| 4894- | Sper, | Application of Spermidine in Cancer Research Models: Notes and Protocols |
| - | Review, | Var, | NA |
| 4895- | Sper, | Spermidine as a target for cancer therapy |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4896- | Sper, | immuno, | Spermidine potentiates anti-tumor immune responses and immunotherapy sensitivity in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 4897- | Sper, | Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms |
| - | Review, | Var, | NA |
| 1512- | Squ, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 107- | SS, | Saikosaponin B1 and Saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway |
| - | vitro+vivo, | MB, | LS174T |
| 1017- | SSE, | Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis |
| - | vitro+vivo, | CRC, | NA |
| 1062- | SSE, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 1018- | SSE, | Selenite-induced autophagy antagonizes apoptosis in colorectal cancer cells in vitro and in vivo |
| - | vitro+vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | SW480 |
| 984- | SSE, | Effects of selenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 1002- | SSE, | Osi, | Adag, | Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H385 |
| - | vitro+vivo, | Lung, | NA |
| 4216- | SSE, | Selenium ameliorates mercuric chloride-induced brain damage through activating BDNF/TrKB/PI3K/AKT and inhibiting NF-κB signaling pathways |
| - | in-vitro, | NA, | NA |
| 4739- | SSE, | Chemo, | Rad, | Therapeutic Benefits of Selenium in Hematological Malignancies |
| - | Review, | Var, | NA |
| - | Trial, | GC, | NA |
| 4727- | SSE, | Selenium inhibits ferroptosis in ulcerative colitis through the induction of Nrf2/Gpx4 |
| - | in-vivo, | Col, | NA |
| 4743- | SSE, | Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid